# Corcept Therapeutics (CORT) EPS: $0.82 in 2025

URL: https://funkfolio.com/stock/CORT/eps

> Corcept Therapeutics (CORT) earnings per share (EPS) was $0.82 in fiscal 2025, down 33.3% from fiscal 2024. Over five fiscal years it shrank 0.7% a year.

---

## Corcept Therapeutics (CORT) earnings per share (EPS)

**Earnings per share · fiscal 2025:** $0.82 year ended Dec 31, 2025

Corcept Therapeutics (CORT) reported diluted earnings per share of $0.82 in fiscal 2025 (the year ended December 31, 2025). That is 33.3% lower than the $1.23 of fiscal 2024. Figures as of 17 Nov 2026, 21:39 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Earnings per share, fiscal 2025:** $0.82
- **Change on fiscal 2024:** −33.3%
- **Growth, 5 years:** −0.7% a year
- **Highest on record:** $1.23 fiscal 2024
- **Lowest on record:** -$0.06 fiscal 2015
- **Fiscal years on record:** 11 2015–2025

Figures as of 17 Nov 2026, 21:39 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Corcept Therapeutics earnings per share (EPS), in more detail

Over the five fiscal years to 2025 diluted earnings per share shrank at a compound 0.7% a year. Across the 11 fiscal years on record (2015–2025), the highest was $1.23 in fiscal 2024 and the lowest -$0.06 in fiscal 2015.

### Earnings per share by fiscal year

### Corcept Therapeutics earnings per share (EPS), year by year

Corcept Therapeutics (CORT) earnings per share (EPS) by fiscal year

| Fiscal year | Earnings per share | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | $0.82 | 33.3% down | Dec 31, 2025 |
| 2024 | $1.23 | 30.9% up | Dec 31, 2024 |
| 2023 | $0.94 | 8.0% up | Dec 31, 2023 |
| 2022 | $0.87 | 2.2% down | Dec 31, 2022 |
| 2021 | $0.89 | 4.7% up | Dec 31, 2021 |
| 2020 | $0.85 | 10.4% up | Dec 31, 2020 |
| 2019 | $0.77 | 28.3% up | Dec 31, 2019 |
| 2018 | $0.60 | 42.3% down | Dec 31, 2018 |
| 2017 | $1.04 | 1,385.7% up | Dec 31, 2017 |
| 2016 | $0.07 | — | Dec 31, 2016 |
| 2015 | -$0.06 | — | Dec 31, 2015 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

### How to read it

It shows how much profit stands behind each share, so it rises when profit grows or when buybacks shrink the share count.

### Earnings per share at health care companies of similar size

Earnings per share of Corcept Therapeutics and comparable companies

| Company | Earnings per share | Fiscal year |
| --- | --- | --- |
| [10x Genomics TXG](https://funkfolio.com/stock/TXG/eps) | -$0.35 | 2025 |
| [HealthEquity HQY](https://funkfolio.com/stock/HQY/eps) | $2.46 | 2026 |
| Corcept Therapeutics CORT | $0.82 | 2025 |
| [Rhythm Pharmaceuticals RYTM](https://funkfolio.com/stock/RYTM/eps) | -$3.11 | 2025 |
| [Alkermes ALKS](https://funkfolio.com/stock/ALKS/eps) | $1.43 | 2025 |
| [PACS Group PACS](https://funkfolio.com/stock/PACS/eps) | $1.22 | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Corcept Therapeutics, figure by figure

- [Corcept Therapeutics market cap](https://funkfolio.com/stock/CORT/market-cap)
- [Corcept Therapeutics revenue](https://funkfolio.com/stock/CORT/revenue)
- [Corcept Therapeutics earnings](https://funkfolio.com/stock/CORT/earnings)
- [Corcept Therapeutics P/E ratio](https://funkfolio.com/stock/CORT/pe-ratio)
- [Corcept Therapeutics P/S ratio](https://funkfolio.com/stock/CORT/ps-ratio)
- [Corcept Therapeutics P/B ratio](https://funkfolio.com/stock/CORT/pb-ratio)
- [Corcept Therapeutics free cash flow](https://funkfolio.com/stock/CORT/free-cash-flow)
- [Corcept Therapeutics operating margin](https://funkfolio.com/stock/CORT/operating-margin)
- [Corcept Therapeutics dividend](https://funkfolio.com/stock/CORT/dividend)
- [Corcept Therapeutics shares outstanding](https://funkfolio.com/stock/CORT/shares-outstanding)
- [Corcept Therapeutics total debt](https://funkfolio.com/stock/CORT/total-debt)
- [Corcept Therapeutics cash on hand](https://funkfolio.com/stock/CORT/cash)
- [Corcept Therapeutics total assets](https://funkfolio.com/stock/CORT/total-assets)
- [Corcept Therapeutics return on equity (ROE)](https://funkfolio.com/stock/CORT/roe)
- [Corcept Therapeutics return on invested capital (ROIC)](https://funkfolio.com/stock/CORT/roic)

[Corcept Therapeutics (CORT) overview: price, valuation and scorecard](https://funkfolio.com/stock/CORT) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Corcept Therapeutics earnings per share (EPS): questions and answers

**What is Corcept Therapeutics's diluted earnings per share?**

Corcept Therapeutics (CORT) reported diluted earnings per share of $0.82 in fiscal 2025 (the year ended December 31, 2025). That is 33.3% lower than the $1.23 of fiscal 2024.

**What is the growth rate of Corcept Therapeutics's diluted earnings per share?**

Over the five fiscal years to 2025 diluted earnings per share shrank at a compound 0.7% a year.

**What are the highest and lowest diluted earnings per share figures on record for Corcept Therapeutics?**

Across the 11 fiscal years on record (2015–2025), the highest was $1.23 in fiscal 2024 and the lowest -$0.06 in fiscal 2015.

**How is Corcept Therapeutics's diluted earnings per share calculated?**

Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.

Fiscal years are named for the calendar year they end in.

### Learn: earnings per share (EPS)

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Revenue vs earnings vs free cash flow: what each tells you](https://funkfolio.com/learn/stocks/revenue-earnings-free-cash-flow)

  Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- [P/E ratio explained: what a high or low figure means](https://funkfolio.com/learn/stocks/pe-ratio)

  The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.

### Cite this page

Funkfolio, “Corcept Therapeutics (CORT) earnings per share (EPS)”, data as of 17 November 2026. https://funkfolio.com/stock/CORT/eps

Underlying data: the company's filings with the SEC and Yahoo Finance.
